The treatment of hepatic encephalopathy

被引：0
作者：
Marsha Y. Morgan
A. Blei
K. Grüngreiff
R. Jalan
G. Kircheis
G. Marchesini
O. Riggio
Karin Weissenborn
机构：
[1] Royal Free Campus,Centre for Hepatology, Division of Medicine
[2] Royal Free and University College Medical School,Institute of Hepatology, Division of Medicine
[3] University College London,Department of Gastroenterology, Hepatology and Infectiology
[4] Northwestern University,Unit of Clinical Dietetics
[5] Hepatology Outpatient Practice,Department of Clinical Medicine, Division of Gastroenterology
[6] Bloomsburg Campus,Department of Neurology
[7] Royal Free and University College Medical School,undefined
[8] University College London,undefined
[9] Heinrich-Heine-University,undefined
[10] Alma Mater Studiorum University,undefined
[11] University of Rome La Sapienza,undefined
[12] Medical School Hannover,undefined
来源：
Metabolic Brain Disease | 2007年 / 22卷
关键词：
Branched-chain amino acids; Bromocriptine; Hepatic cirrhosis; Hepatic encephalopathy; Non-absorbable antibiotics; Non-absorbable disaccharides; Ornithine aspartate; Sodium benzoate; Treatment; Zinc;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
Current recommendations for the treatment of hepatic encephalopathy are based, to a large extent, on open or uncontrolled trials, undertaken in very small numbers of patients. In consequence, there is ongoing discussion as to whether the classical approach to the treatment of this condition, which aims at reducing ammonia production and absorption using either non-absorbable disaccharides and/or antibiotics, should be revisited, modified or even abandoned. Pros and cons of present therapeutic strategies and possible future developments were discussed at the fourth International Hannover Conference on Hepatic Encephalopathy held in Dresden in June 2006. The content of this discussion is summarized.
引用
收藏
页码：389 / 405
页数：16
相关论文
共 306 条
[31]  
Monfort P(2005)Bromocriptine-associated ototoxicity J Clin Gastroenterol 39 540-7202
[32]  
Hernandez-Viadel M(1965)Hospitalizations during the use of rifaximin versus lactulose for the treatment of hepatic encephalopathy Lancet 191 399-1092
[33]  
Rodrigo R(2005)Therapie der schweren Hyperammoniämie World J Gastroenterol 11 7197-1801
[34]  
Montoliu C(1996)Endotoxinemia and benzodiazepine-like substances in compensated cirrhotic patients: A randomized study comparing the effect of rifaximine alone and in association with a symbiotic preparation Hepatology 23 1084-1535
[35]  
Felipo V(2003)Synbiotic modulation of gut flora: effect on minimal hepatic encephalopathy in patients with cirrhosis Gastroenterology 124 1792-58
[36]  
Fleig WE(1982)Long-term effects of Enterococcus faecium SF68 versus lactulose in the treatment of patients with cirrhosis and grade 1–2 hepatic encephalopathy BMJ 285 1534-255
[37]  
Kircheis G(2003)Beneficial effects of a probiotic VSL#3 on parameters of liver dysfunction in chronic liver diseases J Hepatol 38 51-1284
[38]  
Spengler U(1987)Treatment of hepatic encephalopathy by alteration of intestinal flora with Enzyme 38 251-670
[39]  
Görtelmeyer R(1987)Effect of Hepatology 7 1278-217
[40]  
Grüngreiff K(1980)-carnitine in patients with hepatic encephalopathy Gastroenterology 78 663-713
12345678910